Three monkeypox virus (MPV) antibody-secreting murine monoclones were characterized as being of the immunoglobulin Gl isotype, gave a 4+ reaction in the indirect fluorescent-antibody test, gave a positive reaction in the enzyme immunoassay, and did not neutralize MPV. These monoclonal antibodies were determined by the sodium dodecyl sulfate-polyacrylamide gel electrophoresis transblot method to react to a 15,500-molecular-weight MPV polypeptide. This reactivity could not be removed by adsorption to a vaccinia virus-infected cell suspension. The three monoclonal antibodies were specific for MPV when tested against epidemiologically unrelated isolates of cowpox virus, variola virus, vaccinia virus, and MPV.
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Monkeypox virus (MPV) and vaccinia virus (VV) are grouped within the orthopoxvirus genus on the basis of their common serological and biological properties. Differentiation of MPV and VV can be accomplished by examination of their pock morphology on chicken chorioallantoic membranes, growth temperatures, and animal inoculations and by analysis of viral polypeptides by polyacrylamide gel electrophoresis (PAGE). Of the numerous polypeptides shared by MPV and VV, the region between molecular weights (MW) 30,000 and 40,000 reveals differences significant for the grouping of these viruses (3). Other regions that reveal differences are a 15,500-MV polypeptide in MPV and a 102,600-MW polypeptide in VV (5) . Present serological methods (17) for the differentiation of MPV and VV rely on the measurement of residual antibodies after the adsorption of antisera to heterologous viral antigens.
Herpes simplex virus monoclonal antibodies that detect type-specific polypeptide determinants have been used to differentiate herpes simplex virus types 1 and 2 in immunofluorescence and neutralization tests (11) . To date, no MPV-specific monoclonal antibodies have been reported. This study describes the production and selection of three independently derived MPV antibody-secreting mouse monoclones that do not cross-react with VV and the use of the sodium dodecyl sulfate (SDS)-PAGE transblot enzyme immunoassay (EIA) to identify a MPV virion polypeptide that does not share a common antigenic determinant with VV. These monoclones were shown to be specific for MPV when tested against epidemiologically unrelated isolates of cowpox virus, variola virus, VV, and MPV.
MPV Copenhagen strain and VV Wyeth strain were grown in LLC-MK2 monolayers for preparation of antigens used in indirect fluorescent-antibody (IFA) tests, EIA, virus neutralization tests, and SDS-PAGE transblot EIA.
MPV Copenhagen strain was propagated in RK-13 cell cultures for mouse inoculation. BALB/c mice were immunized subcutaneously with 2 x 107 viral particles suspended in Freund complete adjuvant (1:1), 2 weeks later with a similar MPV suspension in Freund incomplete adjuvant (1:1), and 4, 6, and 22 weeks later with only the MPV suspension. At 38 weeks after the first injection, the mice * Corresponding author.
were given boosters intravenously. At 5 days after the final immunization, the spleen cells were fused with myeloma SP 2/0 cells as described by Kohler and Milstein (8) .
Stable hybrid cell lines were screened by EIA (14), the IFA test (12) , and radioimmunoassay (17) against VV and MPV antigens. Three of these hybrid cell lines that secreted antibodies which were strongly reactive with MPV and nonreactive with VV were selected for cloning by limiting dilution. One representative clone from each of the three hybrid cell lines was selected for characterization. All three of the independently derived clones secreted antibody of the immunoglobulin G1 subclass (EIA Cytoscreen I.D. test kit; Seragen, Inc., Boston, Mass.), reacted very strongly with MPV in the IFA test and EIA, and did not neutralize MPV (10) . The MPV-specific IFA staining demonstrated granular intracellular fluorescent bodies, in contrast to MPV-and VV-positive monoclonal staining of infected cells, which demonstrated diffuse fluorescent staining (Fig. 1) .
All three clones were determined by the SDS-PAGE transblot EIA (5, 15) to react to an apparent 15,500-MW MPV polypeptide (Fig. 2) . No reactivity was detected against any of the electrophoretically separated VV polypeptides. MPV and VV hyperimmune rabbit sera were used as controls in the SDS-PAGE transblot EIA. The actual number of polypeptides detected by the polyvalent antisera did not correlate with the possible number of polypeptides present in either the MPV or VV antigens, as indicated by India ink staining (4) (Fig. 2) . The lower number of detectable bands detected by the polyvalent antisera could be accounted for by denaturing or rearrangement by the SDS detergent or by "immunodominance" (1) of the antigenic sites. The denaturing effect of the SDS detergent on the antigens (13) may rearrange conformational determinants that may be physically associated between two different virion polypeptides. Another factor which can prevent the detection of all antigenic polypeptides is that only a limited number of the numerous antigenic sites may be immunodominant, resulting in preferential stimulation of the immune response of the host.
To eliminate the possibility that some polypeptides may have been denatured in the VV antigen but not in the MPV antigen, we adsorbed the monoclones to MPV-and VVinfected cell suspensions and LLC-MK2 cells that were not infected. MPV-infected cells removed the activity. VVinfected cells and uninfected LLC-MK2 cells did not remove the monoclonal antibody activity in the SDS-PAGE transblot EIA. These results indicate that a shared MPV-VV 15,500-MW polypeptide was not present in the untreated VV antigen.
In the competitive binding inhibition assay (7) with various amounts of horseradish peroxidase-conjugated (16) MPV monoclonal antibody and with fixed concentrations of unlabeled homologous and heterologous monoclonal antibodies on MPV antigens, the three clones reacted either with identical epitopes or with epitopes so closely located as to cause binding interference.
Previous findings indicate that no two epidemiologically unrelated herpes simplex virus type 1 or 2 virus (2), rabies virus (9), or flavivirus (6) isolates may be identical. Because of the variations among other virus isolates, eight epidemiologically unrelated MPV isolates (Utrecht, Sierre Leone V70-I-266, Nigeria V71-I-82, Liberia V70-I-187, Zaire V72-I-280, Zaire V75-I-362, Zaire V78-I-2982, and Zaire V80-I-52) were tested by EIA and the IFA test with the three monoclonal antibodies. A total of 7 variola virus isolates (India V74-I-10, Somalia V77-I-1588, Brazil Garcia, England Harvey, England Butler, Ethiopia V73-I-156, and Indonesia V72-I-34), 10 
